Yes, Lokelma (sodium zirconium cyclosilicate) should be given daily for maintenance treatment of chronic hyperkalemia.
For maintenance therapy after initial correction, Lokelma is administered once daily at doses ranging from 5 g every other day to 15 g daily, with 10 g once daily as the standard starting maintenance dose 1.
Dosing Algorithm
Initial Correction Phase (First 48 Hours)
- 10 g three times daily for up to 48 hours to rapidly normalize potassium 2, 1
- This achieves normokalemia in 98% of patients within 48 hours 3
- Onset of action begins within 1 hour 2
Maintenance Phase (After Correction)
- 10 g once daily as the standard maintenance dose 1
- Titrate in 5 g increments at intervals of 1 week or longer based on serum potassium levels 1
- Maintenance dose range: 5 g every other day to 15 g daily 1
- Monitor potassium and adjust accordingly—decrease or discontinue if potassium falls below target range 1
Special Population: Hemodialysis Patients
- Administer only on non-dialysis days 1
- Starting dose: 5 g once daily on non-dialysis days 1
- Consider 10 g once daily if baseline potassium >6.5 mEq/L 1
- Dose range: 5-15 g once daily on non-dialysis days 1
Evidence Supporting Daily Maintenance Dosing
The evidence consistently demonstrates that once-daily dosing effectively maintains normokalemia long-term:
In the HARMONIZE trial, once-daily SZC (5,10, or 15 g) maintained mean serum potassium at 4.4-4.8 mEq/L over 28 days, significantly better than placebo (5.1 mEq/L; P<0.001) 2, 4
The 11-month HARMONIZE open-label extension showed 88% of patients achieved mean serum potassium ≤5.1 mEq/L with once-daily dosing (median dose 10 g) 5
A 12-month phase 3 study demonstrated that 88% of patients maintained potassium ≤5.1 mEq/L with individualized once-daily dosing (mean dose 7.2 g) 3
The DIALIZE study in ESRD patients showed once-daily SZC on non-dialysis days effectively maintained normal pre-dialysis potassium levels over 8 weeks 2
Clinical Rationale for Daily Dosing
Daily dosing is necessary because Lokelma's mechanism requires continuous gastrointestinal presence to bind potassium. Unlike acute interventions that shift potassium intracellularly (insulin, beta-agonists), Lokelma removes potassium from the body by binding it in the GI tract and increasing fecal excretion 2. Without daily administration, potassium levels will rise again as dietary intake continues.
The guideline evidence emphasizes that once-daily dosing during maintenance effectively prevents hyperkalemia recurrence while enabling continuation of life-saving RAAS inhibitor therapy 2, 6. This is critical because 87% of patients on RAAS inhibitors at baseline continued or increased their dose with daily SZC maintenance therapy 3.
Important Caveats
Separate other oral medications by at least 2 hours before or after Lokelma, as it may bind other drugs in the GI tract 1
Monitor for edema, particularly at the 15 g daily dose, as each 5 g contains approximately 400 mg sodium 1. In trials, edema was more common with 15 g daily (14% incidence) compared to lower doses 4
Monitor for hypokalemia during maintenance—10-11% incidence with 10-15 g daily doses 4. Adjust dose downward or discontinue if potassium falls below target 1
Avoid in severe constipation or bowel obstruction, as efficacy is uncertain and GI conditions may worsen 1
The evidence unequivocally supports daily maintenance dosing after initial correction to sustain normokalemia and enable optimal disease-modifying therapy.